Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 3/20 | 0.41 |
| ▸ | AKT1 | P31749 | 10/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | PRKACA | P17612 | 2/20 | 0.31 |
| ▸ | PRKACG | P22612 | 2/20 | 0.31 |
| ▸ | PRKACB | P22694 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11918426 | 0.92 | PIK3CG (0.40) | PIK3CG | |
| SCHEMBL10143208 | 0.92 | PIK3CG (0.42) | PIK3CGAKT1 | |
| SCHEMBL11918403 | 0.91 | PIK3CG (0.41) | PIK3CG | |
| SCHEMBL10143063 | 0.90 | PIK3CG (0.51) | PIK3CG | |
| SCHEMBL10143285 | 0.90 | PIK3CG (0.38) | PIK3CG | |
| SCHEMBL19446315 | 0.90 | PIK3CG (0.38) | PIK3CG | |
| SCHEMBL10174618 | 0.89 | PIK3CG (0.46) | PIK3CGAKT1BACE1KCNH2 | |
| SCHEMBL18948400 | 0.89 | PIK3CG (0.38) | PIK3CG | |
| SCHEMBL10143167 | 0.87 | PIK3CG (0.41) | PIK3CG | |
| SCHEMBL10143177 | 0.85 | PIK3CG (0.44) | PIK3CGKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202784-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120040950-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040950-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | PIK3CG 4/4885AKT1 31/4885BACE1 1836/4885 |
| US-20120202784-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | PIK3CG 4/4885AKT1 31/4885BACE1 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.